STOCK MARKET BSE NSE

Hyderabad firm’s COVID-19 drug 'Favicovid' to hit stands in 10 days

The prescription drug, an oral medication in the form of tablets, would be used to treat mild to moderate cases. It would be available in seven-10 days at hospitals and retail pharmacies.

Published: 25th July 2020 08:00 AM  |   Last Updated: 25th July 2020 08:00 AM   |  A+A-

coronavirus, testing, samples

For representational purposes (Photo | AP)

By Express News Service

HYDERABAD: The antiviral drug for Covid 19, Favipiravir, was launched by Hyderabad-based pharmaceutical company Optimus under the name 'Favicovid'.

The prescription drug, an oral medication in the form of tablets, would be used to treat mild to moderate cases. It would be available in seven-10 days at hospitals and retail pharmacies.

“Favipiravir will be manufactured and marketed as an anti-viral drug — Favicovid 200 mg tablets. It will be produced in Hyderabad, at facilities approved by the USFDA and WHO-GMP,” P Prashanth Reddy, director Optimus Pharma, said.

The firm is looking at manufacturing 1 crore tablets a month. “The price is yet to be decided but it will be competitive,” Reddy said.

While Favipiravir is already in the market with makers such as Glenmark, the product is likely to increase the supply. The medicine offers wide-spectrum antiviral cover for RNA viruses such as SARS-CoV-2 and can reduce viral load within four days of medication.

While the dosage would be prescribed by doctors, the company recommended 1,800 mg twice a day on the first day of the infection, followed by 800 mg twice a day for 14 days or till test reports return negative.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

flipboard facebook twitter whatsapp